TTF2 and frontotemporal dementia: The median PFS, TTF, and TTF2 were, respectively, 4.5, 4.2, and 8.8 months in the FTD/TPI plus bevacizumab group and 6.0, 5.8, and 9.9 months in the control group (Fig. 2b–d).